Holen Sie sich die Stockscreener-App
22.61
6.80%
1.44
Handel nachbörslich:
22.46
-0.15
-0.66%
Maplight Therapeutics Inc Aktie (MPLT) Neueste Nachrichten
MapLight2026 Funding Rounds & List of Investors - Tracxn
Maplight Therapeutics (NASDAQ:MPLT) Reaches New 52-Week HighHere's Why - MarketBeat
MPLT Earnings History & Surprises | EPS & Revenue Results | MAPLIGHT THERAPEUTICS INC (NASDAQ:MPLT) - ChartMill
Stifel Maintains MapLight Therapeutics(MPLT.US) With Buy Rating, Maintains Target Price $28 - 富途牛牛
All News for MPLT : MapLight Therapeutics, Inc. - Zacks Investment Research
Maplight Therapeutics (NASDAQ:MPLT) Issues Quarterly Earnings Results, Misses Estimates By $1.42 EPS - MarketBeat
Maplight Therapeutics, Inc. (NASDAQ:MPLT) Given Average Recommendation of "Moderate Buy" by Analysts - MarketBeat
Sergey Brin Nonprofit Gets $261 Million Lift in MapLight IPO - MSN
MapLight Therapeutics Announces 2025 Financial Results, Advances Clinical Pipeline for Schizophrenia, Autism, and Alzheimer’s Trials - Minichart
Maplight Therapeutics (NASDAQ:MPLT) Shares Up 5.6%What's Next? - MarketBeat
MapLight Therapeutics 2023 Annual Report: Innovative CNS Drug Discovery, Pipeline, and Risk Factors Overview - Minichart
MapLight Therapeutics Highlights Growing CNS Pipeline, Strong Cash Position - TipRanks
Stifel reiterates Buy rating on MapLight Therapeutics stock By Investing.com - Investing.com Canada
Stifel reiterates Buy rating on MapLight Therapeutics stock - Investing.com
MapLight Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
MapLight Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
MapLight Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update - Bitget
MapLight Therapeutics 10-K: Revenue $0, Net loss $161.2M - TradingView
[10-K] MapLight Therapeutics, Inc. Files Annual Report - Stock Titan
Earnings Flash (MPLT) MapLight Therapeutics Posts Q4 Loss $2.47 a Share - MarketScreener
MapLight Therapeutics (NASDAQ: MPLT) widens 2025 loss but funds runway through 2027 - Stock Titan
Two Phase 2 readouts ahead as MapLight says cash lasts through 2027 - stocktitan.net
Top Maplight Therapeutics (MPLT) Competitors 2026 - MarketBeat
MapLight Therapeutics, Inc.(NasdaqGS: MPLT) added to S&P Global BMI Index - MarketScreener
Maplight Therapeutics (NASDAQ:MPLT) Cut to Sell at Wall Street Zen - marketbeat.com
MapLight Therapeutics, Inc.: Fundamental Analysis and Financial Ratings | MPLT | US56565P1030 - marketscreener.com
Canaccord Genuity Group Begins Coverage on Maplight Therapeutics (NASDAQ:MPLT) - MarketBeat
Maplight Therapeutics (NASDAQ:MPLT) Shares Down 3.1%Should You Sell? - MarketBeat
Maplight Therapeutics (NASDAQ:MPLT) Stock Price Up 8.9%Here's What Happened - MarketBeat
MapLight Therapeutics to join Russell 3000, Russell 2000 and Russell Microcap indexes - MSN
MapLight Therapeutics: Sector Dynamics Take Center Stage Amid Company Quiet () - aktiencheck.de
MapLight Therapeutics Director Makes Bold Insider Move in Latest Stock Buy - TipRanks
Schizophrenia Clinical Trial Pipeline Expands as 55+ Pharma Companies Progress Novel Therapies Toward Market Entry, Finds DelveInsight | Sunovion Pharmaceuticals, AbbVie, Karuna Therapeutics - Barchart.com
Autistic Disorder Pipeline Expands with 25+ Companies and 25+ Therapies in Development Across Clinical Stages, Reveals DelveInsight - Barchart
Neumora Therapeutics (NMRA) Positioned to Capitalize on Blockbuster Opportunity - Finviz
Maplight Therapeutics, Inc. (NASDAQ:MPLT) Receives $31.00 Consensus Price Target from Analysts - Defense World
MapLight $251M IPO Defies Market Slowdown Amid Federal Shutdown - USA Herald
MapLight Therapeutics to Participate in Upcoming Investor Conferences - Bitget
Maplight Therapeutics, Inc. (NASDAQ:MPLT) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
MapLight Therapeutics Inc expected to post a loss of 99 cents a shareEarnings Preview - TradingView
MapLight Therapeutics Insider Makes a Major Move With Fresh Stock Sale - TipRanks
Maplight Therapeutics (NASDAQ:MPLT) Director Sells $13,358.40 in Stock - MarketBeat
Insider Selling: Maplight Therapeutics (NASDAQ:MPLT) Director Sells $39,575.85 in Stock - MarketBeat
Insider Selling: Maplight Therapeutics (NASDAQ:MPLT) Director Sells 11,264 Shares of Stock - MarketBeat
Director Malenka sells 14,195 MapLight (MPLT) shares to cover RSU taxes - Stock Titan
MapLight Therapeutics, Inc. Rings the Closing Bell - Nasdaq
MapLight Therapeutics, Inc. Rings the Nasdaq Stock Market Closing Bell - Nasdaq
Maplight Therapeutics (NASDAQ:MPLT) Shares Gap Up After Insider Buying Activity - Defense World
Maplight Therapeutics (NASDAQ:MPLT) Director Acquires $186,301.84 in Stock - Defense World
MapLight Therapeutics Insiders Signal Confidence with Share Purchases () - aktiencheck.de
Insider Buying: George Pavlov Acquires 25,000 Shares of MapLight Therapeutics Inc (MPLT) - GuruFocus
Maplight Therapeutics (NASDAQ:MPLT) Director Acquires $177,171.20 in Stock - MarketBeat
Maplight Therapeutics (NASDAQ:MPLT) Director Acquires $77,694.54 in Stock - MarketBeat
Maplight Therapeutics (NASDAQ:MPLT) Director George Pavlov Purchases 10,658 Shares - MarketBeat
0.87%
0.11%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):